Article
Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
American journal of respiratory and critical care medicine - 1 Nov 2023
McNally Paul, Lester Karen, Stone Gavin, Elnazir Basil, Williamson Michael, Cox Des, Linnane Barry, Kirwan Laura, Rea David, O'Regan Paul, Semple Tom, Saunders Clare, Tiddens Harm A W M, McKone Edward, Davies Jane C
Abstract excerpt
Rationale: Clinical trials have shown that use of elexacaftor/tezacaftor/ivacaftor (ETI) is associated with improvements in sweat chloride, pulmonary function, nutrition, and quality of life in people with cystic fibrosis (CF). Little is known about the impact of ETI on ventilation inhomogeneity and lung structure. Objectives: RECOVER is a real-world study designed to measure the impact of ETI in people with CF....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.